Robert Letterio Oliva Acquires 5,000 Shares of Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Stock

Novo Integrated Sciences, Inc. (NASDAQ:NVOSGet Rating) Director Robert Letterio Oliva bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 19th. The shares were purchased at an average price of $2.23 per share, for a total transaction of $11,150.00. Following the transaction, the director now owns 212,717 shares of the company’s stock, valued at approximately $474,358.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Novo Integrated Sciences stock traded down $0.07 during trading hours on Thursday, reaching $2.20. 9,082 shares of the company’s stock were exchanged, compared to its average volume of 63,419. Novo Integrated Sciences, Inc. has a 52-week low of $1.02 and a 52-week high of $3.32. The company has a fifty day moving average of $2.03 and a 200-day moving average of $1.67. The company has a current ratio of 1.65, a quick ratio of 1.62 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $65.81 million, a price-to-earnings ratio of -6.68 and a beta of -0.24.

Novo Integrated Sciences (NASDAQ:NVOSGet Rating) last released its earnings results on Tuesday, January 18th. The company reported ($0.06) EPS for the quarter. Novo Integrated Sciences had a negative net margin of 80.71% and a negative return on equity of 16.63%. The business had revenue of $3.16 million during the quarter.

Several hedge funds have recently made changes to their positions in NVOS. Morgan Stanley purchased a new position in Novo Integrated Sciences during the second quarter worth approximately $288,000. Citadel Advisors LLC acquired a new stake in shares of Novo Integrated Sciences during the 2nd quarter worth $30,000. Finally, Millennium Management LLC purchased a new position in shares of Novo Integrated Sciences in the 2nd quarter worth $111,000. Institutional investors and hedge funds own 12.48% of the company’s stock.

Novo Integrated Sciences Company Profile (Get Rating)

Novo Integrated Sciences, Inc, together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services.

Featured Articles

Receive News & Ratings for Novo Integrated Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Integrated Sciences and related companies with MarketBeat.com's FREE daily email newsletter.